Eurofins Worldwide
Careers at Eurofins
Eurofins in your country
2007
ICAAC
1. Analysis of Doripenem Activity, Relative to Other Carbapenems, Against Target Gram-Negative Pathogens Isolated From Specific Infection Sites
2. A Longitudinal Perspective of Tigecycline Activity in the US against Staphylococcus aureus, Acinetobacter spp., and Enterobacteriaceae Exhibiting Multi-drug Resistant (MDR) Phenotypes
3. A Profile of Ceftobiprole (BPR) Activity Against Recent US Isolates of Enterobacteriaceae (EN) and Pseudomonas aeruginosa (PA) From Inpatients and ICU Patients
4. In Vitro activity of iclaprim against clinical isolates of Legionella pneumophila
5. Baseline Surveillance Profile of Cethromycin Activity against Streptococcus pneumoniae (SP); Results of the US Surveillance Initiative
6. Stratified Analysis of Doripenem Activity Against Enterobacteriaceae and Pseudomonas aeruginosa According to Patient Location: Inpatients and ICU Patients
7. Comparative Activities of Tigecycline among Recent Surveillance Isolates Tested by E-test and Broth Microdilution
8. 5-Year Surveillance (2003-2007) of Anti-pneumococcal Activity of Oral Agents Recommended for the Empirical Treatment of Community Aquired Pneumonia (CAP) in Adults
9. Anti-Streptococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use against Gram-Positive Infections
10. In Vitro Activity Profile of Oritavancin against Resistant Staphylococcal Populations from a Recent Surveillance Initiative
11. In Vitro Activity Profile of Ceftobiprole (BPR), a Broad-Spectrum Anti-MRSA Cephalosporin, Against Recent S. aureus (SA) Isolated From Specific Clinical Specimens
12. In Vitro Activity of Cethromycin against a Recent and Diverse Collection of Haemophilus influenzae Isolates
13. Newly Defined in Vitro Quality Control Ranges for Oritavancin Broth Microdilution Testing and the Effect of Variations in Testing Conditions on MIC Results
14. Anti-Enterococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use against Gram-Positive Infections
15. In Vitro Activity Profile of Oritavancin against a Broad Spectrum of Aerobic and Anaerobic Bacterial Pathogens
16. Bactericidal activity and post antibiotic effect of iclaprim (ICL) against Staphylococcus aureus (SA)
17. Iclaprim (ICL): Defined quality control (QC) limits for MIC and disk diffusion (DD) susceptibility testing according to CLSI M23-A2 procedures
18. In Vitro Activity Profile of Oritavancin (ORI) against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents
IDSA
1. Analysis of Levofloxacin and Comparator Antibiograms against Urinary Tract Infection (UTI) Isolates of E. coli and Other Enterobacteriaceae Across the United States
2. Surveillance Profiling of Doripenem Activity Against Pseudomonas aeruginosa Isolated From Inpatients and ICU Patients: Results of the TRUST Surveillance Initiatives
3. Ceftobiprole (BPR) Activity Against MRSA Stratified According to Patient Population and Specimen Source: Results of the Recent TRUST Surveillance Initiative
ECCMID
1. Europe Surveillance Initiative Profiling the Activity of Telavancin Against Streptococci by Specimen Source From 2004 to 2005
2. Baseline Surveillance Profile of Doripenem Against Key Gram-Negative Pathogens Encountered in Europe
3. Profile of Ceftobiprole Activity Against S. aureus, S. pneumoniae, Enterobacteriaceae, P. aeruginosa and Acinetobacter spp.: Results of the 2005-2006 Surveillance Program
4. Europe Surveillance Initiative Profiling the Anti-staphylococcal Activity of Telavancin by Specimen Source from 2004 to 2005
5. Europe Surveillance Initiative Profiling the Anti-enterococcal Activity of Telavancin by Specimen Source from 2004 to 2005
6. Analysis of Tigecycline Activity against Acinetobacter spp. and Enterobacteriaceae Based on Clinical Specimen Source
7. Current Susceptibility Patterns for Streptococcus pneumoniae and Haemophilus influenzae Isolates from Europe: Findings of the 2005-2006 GLOBAL Surveillance Program
8. Evalutation of Isavuconazole E-test Compared to Broth Microdilution Antifungal Susceptibility Testing against Quality Control Strains and Clinical Candida Isolates
9. Baseline Profile of RO4908463 (CS-023) against Recent Isolates of Target Gram-Negative Pathogens Exhibiting ß-Lactam Resistant Phenotypes from Europe (EU), 2003-2006
10. Comparison of Baseline Profiles of RO4908463 (CS-023) against Recent Isolates of Target Gram-Possitive Pathogens Exhibiting Key Resistance Phenotypes Obtained from Europe and the USA 2003-2006
2006
1. Increasing Prevalence of High Level Macrolide Resistance among Streptococcus pneumoniae in the United States
2. Comparative In Vitro Potency of Oritavancin, Teicoplanin, and Vancomycin against Glycopeptide-Susceptible and -Resistant Gram-Positive Organisms
3. Baseline Profile of Telavancin Activity against Streptococci: Results of the 2004-2005 US Surveillance Initiative
4. Interaction of Telavancin and Other Antrimicrobial Agents Tested against Key Gram-positive Species
5. In Vitro of Telavancin against Enterococci: Results of the 2004-2005 US Surveillance Initiative
6. Baseline Antistaphylococcal Profile of Telavancin: Results of the 2004-2005 US Surveillance Initiative
7. In Vitro Activity of API-1252, a Novel Antimicrobial Agent, against Select Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Exhibiting Key Resistance Phenotypes
8. Activity of ME1036, a Novel Anti-MRSA Carbapenem, against Gram-Positive and Gram-Negative Pathogens
9. Baseline Profile of RO4908463 (CS-023) Against Recent Isolates of Target Gram-Positive Pathogens Exhibiting Key Resistance Phenotypes
10. Profile of Ceftobiprole (BPR) Activity Against Staphylococci and S. pneumoniae (SP): Results fo the 2005-2006 Surveillance Program
11. Baseline Surveillance Profiles of Ceftobiprole (BPR) Activity Against Enterobacteriaceae and P. aeruginosa (PA)
12. Discordant Levofloxacin (LV) and Ciprofloxacin (CP) Susceptibility Profiles among Common Gram-Negative Bacilli; Indication of Potential Differences in Mode of Action?
13. Telavancin Demonstrates a Low Potential for In Vitro Selection of Resistance among Key Target Gram-positive Species
14. Bactericidal Activity of RO4908463 (CS-023) Against Beta-Lactam-Susceptible and -Resistant Target Species
15. Baseline Profile of RO4908463 (CS-023) Against Recent Isolates of Target Gram-Negative Pathogens Exhibiting Beta-Lactam Resistance Phenotypes
16. RO4908463 (CS-023) Demonstrates a Low Potential for in vitro Selection of Resistance in S. aureus, S. pneumoniae, E. coli, E. cloacae, K. pneumoniae and P. aeruginosa
17. Surveillance of Tigecycline (TIG) Activty; Discordance between Natioinal Profiles Associated with Testing Protocol and Methods
18. Longitudinal Analysis of Tigecycline (TIG) Activity against Geographically Diverse Staphylococcus aureus (SA), Acinetobacter spp (AB), and Enterobacteriaceae (EN) Exhibiting Multi-drug Resistant (MDR) Penotypes
1. Profiles of Tigecycline Activity Based on Patient Location and Clinical Specimen Source of Target Organisms
2. Baseline Surveillance of Telavancin In Vitro Activity against Staphylococci in Europe and Israel
3. Baseline Surveillance of Telavancin Activity against Enterococci in Europe and Israel
4. Antistreptococcal Profile of Telavancin Based of the 2004-2005 Surveillance Initiative in Europe and Israel
5. Fluoroquinolone Susceptibility Profiles of Recent Urinary Tract Isolates Obtained from Pediatric Patients
6. Increasing Prevalence of Multidrug Resistance Phenotypes among Staphylococcus aureus Encountered in the Outpatient Settings; Comparative Findings of the LEADER 2004 and 2005 Surveillance Programs
7. Longitudinal Analysis of Linezolid (LIN) Activity against Gram-positive Pathogens: Comparison of Results for the LEADER 2004 and 2005 US Surveillance Programs
8. Comparative Susceptibility Patterns of Levofloxacin and Other Agents against Pediatric Respiratory Tract Isolates of Streptococcus pneumoniae (SP)
1. A Current Perspective on Streptococcus pneumoniae and Haemophilus influenzae Resistance Trends in Europe: GLOBAL Surveillance Study 2005
2. Comparative Analysis of Levofloxacin and Ciprofloxacin Activity against Gram-Negative Pathogens Collected in Five European Countries Grouped by Site of Infection from GLOBAL Surveillance - 2005
3. Benchmarking Tigecycline Activity against Gram-positive and Gram-negative Pathogens with Multi-drug Resistance Phenotypes derived from Patient Specimens from the USA and Europe
2005
1. Screening of Levofloxacin-Susceptible Streptococcus pneumoniae Isolates from Clinical Trial Patients with Pneumonia for Mutations in parC or parE: Clinical and Microbiological Outcomes
2. Baseline Tigecycline (TIG) Activity Against Current and Geographically Diverse Staphylococcus aureus (SA) Strains Exhibiting Key Resistance Phenotypes
3. Comparison of Antimicrobial Resistance Profiles between Inpatient and Outpatient Escherichia coli Populations
4. Telavancin Activity Against Current and Diverse Staphylococcus aureus Populations
5. Telavancin Activity Against Current and Diverse Populations of Enterococci and Streptococcus pneumoniae
6. In vitro Activity of Linezolid Against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program
7. Comparative Analysis of Antimicrobial Phenotypes between Streptococcus pneumoniae Populations Isolated from the Community and Hospital Settings
8. In Vitro Potency and Spectrum of Novel Rifamycins ABI-0043, ABI-0094, and ABI-0299
9. In Vitro Activity of Retapamulin and Comparators against 1690 Recent Gram-Positive Clinical Isolates
10. Dalbavancin Demonstrates a Low In Vitro Potential for Selection of Resistance in Staphylococci
1. Antimicrobial Resistance Trends Among Sinus Isolates of Streptococcus pneumoniae from the United States: 2000-2005
2. Role of Efflux and QRDR Mutations among Streptococcus pneumoniae Isolates with Reduced Susceptibilities to Ciprofloxacin
3. Baseline Tigecycline (TIG) Activity Against a Diverse and Current Collection of Enterobacteriaceae (EB) and Acinetobacter (AC) Exhibiting Multi-drug Resistnace
4. Current Antimicrobial Resistance Profiles Among Methicillin-Resistant Staphylococcus aureus Encountered in the Outpatient Setting: Analysis of LEADER 2004 Surveillance Program Results
5. Ceftobiprole (BAL9141), an Investigational Cephalosporin With Activity Against MRSA, Demonstrates In Vitro Activity Against Clinical Isolates of Pseudomonas aeruginosa
1. A Baseline Assesment of the Activity of Telavancin against a Collection of Gram-Positive Isolates, including Resistant Phenotypes
2. Activity and Pharmacodynamics of RO4908463 (CS-023), a Unique Guanidine-Pyrrolidine Carbapenem with Activity against MRSA
3. Investigation of Divergent Piperacillin and Piperacillin/tazobactam Activities to Support Appropriate Formulary Decisions
4. The Prevalence of Multidrug Resistance Among Streptococcus pneumoniae (SP) in the USA
5. Activity of Ceftobiprole against Recent Clinical Isolates of Enterobacteriaceae from Respiratory Infections from Hospitalized Patients in Europe and USA
Eurofins in your country